StockData
Metagenomi Therapeutics, Inc. logo

Metagenomi Therapeutics, Inc. (MGX) stock

MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.63+0.00 (+0.13%)

Close on Nov 18, 2026Market cap $23.87MP/E –Yield –

Metagenomi Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Metagenomi Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$100.57M. For fiscal 2025 it was -$96.01M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$96.01M–
FY2024Dec 31, 2024-$88.90M–
FY2023Dec 31, 2023-$78.49M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$28.77M–
Q1 FY2026Mar 31, 2026-$24.59M–
Q4 FY2025Dec 31, 2025-$24.37M–
Q3 FY2025Sep 30, 2025-$22.84M–
Q2 FY2025Jun 30, 2025-$20.99M–
Q1 FY2025Mar 31, 2025-$27.82M–
Q4 FY2024Dec 31, 2024-$20.62M–
Q3 FY2024Sep 30, 2024-$22.38M–
Q2 FY2024Jun 30, 2024-$16.86M–
Q1 FY2024Mar 31, 2024-$29.03M–
Q4 FY2023Dec 31, 2023-$20.20M–
Q3 FY2023Sep 30, 2023-$22.40M–
Q2 FY2023Jun 30, 2023-$17.96M–
Q1 FY2023Mar 31, 2023-$17.94M–

More Metagenomi Therapeutics figures

See a number that looks wrong?